Time filter

Source Type

Rech E.L.,Synthetic Biology and Nanotechnology Group | Arber W.,University of Basel
Annals of Applied Biology | Year: 2013

Plant and animal domestication form the foundation of agriculture. Currently, there are considerable efforts and hypotheses to understand adaptation and regulatory processes involving domestication and biodiversity organisms. Here, we propose the use of recombinant DNA as a foundation for the synthetic domestication of biodiversity traits. For example, we commented on current studies involving synthetic spider-like fibres production in bacteria and mimicking oil seed species in genetically manipulated soybean. We suggest that this approach constitutes a sustainable and viable option for conservation and development of value-added processes and products from biodiversity. © 2013 Association of Applied Biologists. Source

da Cunha N.B.,Synthetic Biology and Nanotechnology Group | Vianna G.R.,Synthetic Biology and Nanotechnology Group | da Almeida Lima T.,Synthetic Biology and Nanotechnology Group | Rech E.,Synthetic Biology and Nanotechnology Group
Biotechnology Journal | Year: 2014

Plants have emerged as an attractive alternative to the traditional mammalian cell cultures or microbial cell-based systems system for the production of valuable recombinant proteins. Through recombinant DNA technology, plants can be engineered to produce large quantities of pharmaceuticals and industrial proteins of high quality at low costs. The recombinant production, by transgenic plants, of therapeutic proteins normally present in human plasma, such as cytokines, coagulation factors, anticoagulants, and immunoglobulins, represents a response to the ongoing challenges in meeting the demand for therapeutic proteins to treat serious inherited or acquired bleeding and immunological diseases. As the clinical utilization of fractionated plasma molecules is limited by high production costs, using recombinant biopharmaceuticals derived from plants represents a feasible alternative to provide efficient treatment. Plant-derived pharmaceuticals also reduce the potential risks to patients of infection with pathogens or unwanted immune responses due to immunogenic antigens. In this review, we summarize the recent advances in molecular farming of cytokines. We also examine the technological basis, upcoming challenges, and perspectives for the biosynthesis and detection of these molecules in different plant production platforms. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. Source

Discover hidden collaborations